Clinical calculator summary
IPSET Thrombosis Score
Clinical calculator summary
IPSET Thrombosis Score
The International Prognostic Score for Essential Thrombocythemia (IPSET) predicts thrombosis risk in essential thrombocythemia patients to guide antiplatelet or cytoreductive therapy decisions.
Evidence-based context for fast calculator use
- Purpose:
- Stratify thrombosis risk in essential thrombocythemia (low, intermediate, or high risk)
- Population:
- Patients diagnosed with essential thrombocythemia (ET)
- Factors:
- Age >60 years, Cardiovascular risk factors, JAK2 V617F mutation, Prior thrombosis
- Reference:
- Barbui et al., Blood 2012
IPSET-Thrombosis (Essential Thrombocythemia)
Clinical Context & Background
Points: Age > 60 (1), History of Thrombosis (2), JAK2 V617F (2), CV Risk Factors (1).Reference Data
| Risk Group | Total Score | Thrombosis Risk (%/yr) |
|---|---|---|
| Very Low | 0 | 1.03% |
| Low | 1 | 2.35% |
| Intermediate | 2 | 2.86% |
| High | ≥ 3 | 3.56% |
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
When To Use
- Use after essential thrombocythemia has been diagnosed and a thrombotic-risk category is needed for clinic documentation or treatment discussion.
- Use the original point-based IPSET score when cardiovascular risk factors should be explicitly represented in the score.
- Use alongside revised IPSET language when the care plan follows the modern four-category age, thrombosis-history, and JAK2 framework.
How To Interpret
- The score estimates thrombosis risk; it does not estimate bleeding risk, transformation risk, or symptom burden.
- Prior thrombosis and JAK2 V617F carry the largest point weight in the original score.
- A higher category supports aspirin/cytoreductive therapy discussion, but treatment is not automatic from the score alone.
What To Do Next
- Confirm ET diagnosis and exclude reactive thrombocytosis, prefibrotic myelofibrosis, PV, CML, or another myeloid disorder before applying the score.
- Assess aspirin suitability by checking bleeding history, platelet count, acquired von Willebrand syndrome risk, anticoagulant use, and gastrointestinal risk.
- Optimize cardiovascular risk factors even when using revised IPSET, because hypertension, diabetes, smoking, and lipids remain actionable.
Limitations
- Do not apply IPSET to non-ET thrombocytosis or other myeloproliferative neoplasms.
- Do not use thrombosis-risk category alone to prescribe aspirin or cytoreduction without bleeding and patient-context review.
- Pregnancy, fertility planning, extreme thrombocytosis, and unusual-site thrombosis require specialist interpretation beyond this calculator.
Validated Population
Developed for WHO-defined essential thrombocythemia cohorts; clinical use should be reconciled with current hematology guidelines and local ET pathways.
Clinical Example
A 45-year-old JAK2-positive patient without previous thrombosis may be low risk by revised IPSET but still needs aspirin suitability and cardiovascular-risk review. A 72-year-old JAK2-positive patient or anyone with prior thrombosis generally needs a higher-intensity discussion.
Related Tools
Frequently Asked Questions
What is the difference between original and revised IPSET-Thrombosis?
Original IPSET-Thrombosis uses a point score that includes age, prior thrombosis, JAK2 mutation, and cardiovascular risk factors. Revised IPSET-Thrombosis is commonly discussed as a simplified clinical framework emphasizing age, thrombosis history, and JAK2 mutation status.
Does a high IPSET-Thrombosis score automatically mean cytoreductive therapy is required?
No. The score supports risk discussion, but treatment decisions should consider bleeding risk, platelet count, acquired von Willebrand syndrome, comorbidities, patient factors, and current hematology guidelines.
Evidence-based oncology decision support. Verify with clinical guidelines.